ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
unbiased
|
85 |
21K |
11 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
21K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Change of Registered Office and Principal Place of Business
|
|
unbiased
|
17 |
4.5K |
2 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
17
|
4.5K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Change of Registered Office and Principal Place of Business
|
|
unbiased
|
17 |
4.5K |
27 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
17
|
4.5K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
unbiased
|
261 |
72K |
4 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
72K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
unbiased
|
261 |
72K |
2 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
72K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 200 PAA holders as at 29 Feb 2024
|
|
unbiased
|
11 |
3.5K |
10 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
11
|
3.5K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
unbiased
|
209 |
51K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
51K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting & Proxy Form
|
|
unbiased
|
8 |
2.5K |
5 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
8
|
2.5K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting & Proxy Form
|
|
unbiased
|
8 |
2.5K |
4 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
8
|
2.5K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting & Proxy Form
|
|
unbiased
|
8 |
2.5K |
6 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
8
|
2.5K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAA SHAREHOLDERS AS AT 31/01/2024
|
|
unbiased
|
4 |
1.8K |
3 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
4
|
1.8K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
unbiased
|
30 |
6.2K |
8 |
30/12/23 |
30/12/23 |
ASX - By Stock
|
30
|
6.2K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
unbiased
|
30 |
6.2K |
12 |
30/12/23 |
30/12/23 |
ASX - By Stock
|
30
|
6.2K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
unbiased
|
30 |
6.2K |
4 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
30
|
6.2K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
unbiased
|
30 |
6.2K |
4 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
30
|
6.2K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
unbiased
|
30 |
6.2K |
6 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
30
|
6.2K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
unbiased
|
30 |
6.2K |
7 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
30
|
6.2K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Shareholders as at 31 October 2023
|
|
unbiased
|
8 |
2.1K |
2 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
8
|
2.1K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
TOP 200 PAA SHAREHOLDERS AS AT 29 SEPTEMBER 2023.
|
|
unbiased
|
6 |
1.9K |
4 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
6
|
1.9K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 SHAREHOLDERS AS AT 31 AUGUST 2023
|
|
unbiased
|
3 |
1.3K |
2 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
3
|
1.3K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Holders of Unlisted Options expiring 30/04/2026
|
|
unbiased
|
2 |
710 |
1 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
2
|
710
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Pharmaust Option Holders as at 30th March 2023
|
|
unbiased
|
14 |
4.5K |
6 |
01/04/23 |
01/04/23 |
ASX - By Stock
|
14
|
4.5K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Option Holders as at 28 February 2023, with variations
|
|
unbiased
|
3 |
1.6K |
4 |
03/03/23 |
03/03/23 |
ASX - By Stock
|
3
|
1.6K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Option Holders as at 28 February 2023, with variations
|
|
unbiased
|
3 |
1.6K |
6 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
3
|
1.6K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Top 1Top 100 PAA Share Holders as at 28 February 2023, with variations
|
|
unbiased
|
2 |
1.2K |
5 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
2
|
1.2K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Shareholders as at 31/10/2022
|
|
unbiased
|
5 |
2.0K |
5 |
03/10/22 |
03/10/22 |
ASX - By Stock
|
5
|
2.0K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
unbiased
|
1.4K |
376K |
0 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
1.4K
|
376K
|
0
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
unbiased
|
1.4K |
376K |
1 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
1.4K
|
376K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders as at 31 October 2022 with variations
|
|
unbiased
|
9 |
2.5K |
2 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
9
|
2.5K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders as at 31 October 2022 with variations
|
|
unbiased
|
9 |
2.5K |
4 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
9
|
2.5K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 shareholders with variations as at 30 June 2022:
|
|
unbiased
|
6 |
1.9K |
1 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
6
|
1.9K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
unbiased
|
1.4K |
376K |
1 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
1.4K
|
376K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders With Variations May 2022
|
|
unbiased
|
3 |
1.0K |
3 |
01/06/22 |
01/06/22 |
ASX - By Stock
|
3
|
1.0K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on Manufacture of MPL & Tablets for Clinical Trials
|
|
unbiased
|
16 |
4.2K |
8 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
16
|
4.2K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders as at 31 January 2022 with variations
|
|
unbiased
|
3 |
1.0K |
1 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
3
|
1.0K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Top 20 Holders - 31/12/21
|
|
unbiased
|
17 |
5.2K |
3 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
17
|
5.2K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Top 50 as at 29 October with variations.
|
|
unbiased
|
15 |
3.5K |
6 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
15
|
3.5K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Top 50 as at 31 July 2021 with variations
|
|
unbiased
|
4 |
1.5K |
7 |
04/08/21 |
04/08/21 |
ASX - By Stock
|
4
|
1.5K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
unbiased
|
197 |
35K |
1 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
197
|
35K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Top Twenty 30 June 2021 with variations
|
|
unbiased
|
10 |
3.0K |
4 |
03/07/21 |
03/07/21 |
ASX - By Stock
|
10
|
3.0K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Top 50 Shareholders
|
|
unbiased
|
29 |
6.9K |
2 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
29
|
6.9K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 20 as at 31 May 2021
|
|
unbiased
|
13 |
2.6K |
2 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
13
|
2.6K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 20 as at 31 May 2021
|
|
unbiased
|
13 |
2.6K |
7 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
13
|
2.6K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Top 20 as at 31 May 2021
|
|
unbiased
|
13 |
2.6K |
5 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
13
|
2.6K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Charting PAA
|
|
unbiased
|
899 |
204K |
4 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
899
|
204K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
HC PAA SH Volume
|
|
unbiased
|
180 |
40K |
4 |
05/10/20 |
05/10/20 |
ASX - By Stock
|
180
|
40K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Elanco Option Update
|
|
unbiased
|
194 |
50K |
5 |
13/09/20 |
13/09/20 |
ASX - By Stock
|
194
|
50K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Elanco Option Update
|
|
unbiased
|
194 |
50K |
5 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
194
|
50K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Elanco Option Update
|
|
unbiased
|
194 |
50K |
5 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
194
|
50K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust - The Saviour of Global Populations?
|
|
unbiased
|
41 |
8.6K |
2 |
21/08/20 |
21/08/20 |
ASX - By Stock
|
41
|
8.6K
|
2
|
|